Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Genitourinary Cancers: Clinical Advances and Practice Updates
share announcement

Genitourinary Cancers: Clinical Advances and Practice Updates

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Nephrology & Urology".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 424

Special Issue Editors

Dr. David Benjamin

E-Mail Website
Guest Editor
Hoag Family Cancer Institute, Newport Beach, CA 92663, USA
Interests: genitourinary cancers; including prostate; bladder; kidney and testicular cancer
Dr. Arash Rezazadeh Kalebasty

E-Mail Website
Guest Editor
Division of Hematology and Oncology, Department of Medicine, University of California Irvine Medical Center, Orange, CA 92868, USA
Interests: genitourinary oncology; immunotherapy and targeted therapies for cancers of the prostate; bladder; kidney and testes

Special Issue Information

Dear Colleagues,

Genitourinary malignancies, including prostate, bladder, and kidney cancer, compromise some of the most prevalent cancers globally. The medical and surgical management of these cancers generally follow consensus guidelines. However, the management of rare genitourinary cancers, such as penile and urachal cancer, as well as bladder and kidney cancer of variant histology, is unclear. The purpose of this Special Issue is to provide a forum for the latest research and guidance on managing these rare genitourinary cancers.

We invite the submission of original clinical studies, reviews, and state-of-the-art manuscripts that explore these topics, with the goal of advancing treatment approaches and improving patient outcomes across genitourinary malignancies.

Dr. David Benjamin
Dr. Arash Rezazadeh Kalebasty
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • rare tumors
  • genitourinary cancers
  • urachal cancer
  • penile cancer
  • testicular cancer
  • variant histology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

10 pages, 550 KiB  
Article
Predictors of Inguinal Lymph Node Metastasis in Penile Squamous Cell Carcinoma: Insights from a Single-Center Retrospective Study
by Francesco Passaro, Luigi Napolitano, Antonio Tufano, Roberto La Rocca, Claudio Marino, Biagio Barone, Luigi De Luca, Ugo Amicuzi, Michelangelo Olivetta, Francesco Mastrangelo, Pasquale Reccia, Felice Crocetto, Lorenzo Romano, Francesco Paolo Calace, Lorenzo Spirito, Celeste Manfredi, Davide Arcaniolo, Antonio De Palma, Carmine Turco, Carmine Sciorio, Vincenzo Maria Altieri, Gennaro Mattiello, Ernesto di Mauro, Giuseppe Celentano and Sisto Perdonàadd Show full author list remove Hide full author list
J. Clin. Med. 2025, 14(9), 2921; https://doi.org/10.3390/jcm14092921 - 23 Apr 2025
Viewed by 254
Abstract
Background: Squamous cell carcinoma (SCC) of the penis accounts for approximately 95% of penile cancers and is associated with substantial morbidity and mortality. SCC typically develops in uncircumcised men, most commonly affecting the foreskin or glans. While slow-growing, early detection is crucial to [...] Read more.
Background: Squamous cell carcinoma (SCC) of the penis accounts for approximately 95% of penile cancers and is associated with substantial morbidity and mortality. SCC typically develops in uncircumcised men, most commonly affecting the foreskin or glans. While slow-growing, early detection is crucial to improve survival outcomes. Risk factors include advanced age, lack of circumcision, poor hygiene, HPV infection (types 16 and 18), chronic inflammation, and smoking. Methods: We conducted a retrospective, single-center study at IRCCS Hospital “G. Pascale” of Naples, Italy, involving 59 patients treated between January 2015 and January 2023. The inclusion criteria were surgically treated primary tumors, confirmed SCC pathology, and pathologically verified inguinal lymph node metastasis (ILNM). We analyzed clinical variables including lymph node involvement, lymphovascular invasion (LVI), spongiosum corpus involvement (SCI), HPV infection, and tumor differentiation. Univariate and multivariate logistic regression analyses were performed to determine independent predictors of ILNM. Results: The mean age of patients was 66.67 ± 13.97 years. ILNM was confirmed in 24 patients (40.6%), while 35 (59.3%) had no lymph node involvement. Univariate analysis identified lymph node involvement at diagnosis (p = 0.005), LVI (p = 0.003), and SCI (p = 0.003) as significant predictors of ILNM. These factors were confirmed in the multivariate analysis, with lymph node involvement (p = 0.004), LVI (p = 0.025), and SCI (p = 0.028) as independent predictors. Conclusions: Lymph node status, LVI, and SCI are significant predictors of ILNM in penile SCC. Identifying these factors can aid in risk stratification, optimizing surgical decisions, and potentially reducing unnecessary morbidity. Further large-scale studies are recommended to validate these findings and refine prognostic models. Full article
(This article belongs to the Special Issue Genitourinary Cancers: Clinical Advances and Practice Updates)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop